Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Logothetis

Showing results (311-320 of 383) with videos related to

Pageof 39
Sort By:
Endocrine-Related Cancer|September 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotypeNeha Venkatesh, Rebecca S Tidwell, Yao Yu, et al.
Prostate Cancer and Prostatic Diseases|September 13, 2022
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormonesMinas J Sakellakis, Andrew W Hahn, Sumankalai Ramachandran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancerLouis L Pisters, Curtis A Pettaway, Patricia Troncoso, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal of the National Cancer Institute|February 27, 2009
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancerDimitra Tsavachidou, Timothy J McDonnell, Sijin Wen, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Oncogene|September 2, 2021
P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasisMing Zhu, Ruiqing Peng, Xin Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasesPaul Mathew, Peter F Thall, Corazon D Bucana, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
JCO Oncology Practice|November 7, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone TherapyNeha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida, et al.
Pageof 39

Showing results (311-320 of 383) with videos related to

Sort By:
Pageof 39
Endocrine-Related Cancer|September 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotypeNeha Venkatesh, Rebecca S Tidwell, Yao Yu, et al.
Prostate Cancer and Prostatic Diseases|September 13, 2022
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormonesMinas J Sakellakis, Andrew W Hahn, Sumankalai Ramachandran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancerLouis L Pisters, Curtis A Pettaway, Patricia Troncoso, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal of the National Cancer Institute|February 27, 2009
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancerDimitra Tsavachidou, Timothy J McDonnell, Sijin Wen, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Oncogene|September 2, 2021
P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasisMing Zhu, Ruiqing Peng, Xin Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasesPaul Mathew, Peter F Thall, Corazon D Bucana, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
JCO Oncology Practice|November 7, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone TherapyNeha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida, et al.
Pageof 39